 |
38 Diseases |  |
3 Trials |
|
3 Trials |  |
44 News |  |
- || TroVax (MVA 5T4) / Oxford Biomedica
Clinical, P2 data, Journal: A randomized phase II trial to examine modified vaccinia Ankara-5T4 vaccine in patients with relapsed asymptomatic ovarian cancer (TRIOC). (Pubmed Central) - Aug 5, 2024
P2
The majority of patients who received MVA-5T4 had clinical intervention later than those assigned to placebo. NCT01556841.
- TroVax (MVA 5T4) / Oxford Biomedica
Characterization Of PD-1 And PD-L1 Expression In The Tumour Microenvironment Of Ovarian Cancer Using Fluorescence Immunohistochemistry: Results From The TRIOC Trial (Poster area) - Jan 18, 2024 - Abstract #ESGO2024ESGO_1368;
We also studied the significance of PD-1 expression by the T-lymphocytes and PD-L1 expression by either tumor cells or TAMs of which none was associated with significant differences in survival. Figure 1 shows an example of multiplex staining demonstrating the presence of PDL1 expression.Conclusion The expression of PD-L1, PD-1, and CD8, in ovarian tumour tissue, does not correlate with clinical response to the MVA-5T4 vaccination.
- || Opdivo (nivolumab) / Ono Pharma, BMS
Clinical, P1 data, Journal: Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial. (Pubmed Central) - May 22, 2021
P1
It remains to be seen if this vaccination strategy generates immune responses of sufficient magnitude to mediate clinical efficacy and whether it can be effective in late-stage PCa settings, as a monotherapy in advanced disease or as part of multi-modality PCa therapy. To address these questions, the phase I/II trial, ADVANCE, is currently recruiting patients with intermediate-risk PCa, and patients with advanced metastatic castration-resistant PCa, to receive this vaccine in combination with nivolumab.
- TroVax (MVA 5T4) / Oxford Biomedica
[VIRTUAL] TRIOC-A randomised phase II trial to examine MVA-5T4 vaccine in patients with relapsed asymptomatic epithelial ovarian, fallopian tube or primary peritoneal cancer (On-Demand) - Jul 21, 2020 - Abstract #ESMO2020ESMO_1088;
P2
Funding: Oxford Biomedica. Clinical trial identification: EudraCT: 2011-001836-44.
- TroVax (MVA 5T4) / Oxford Biomedica, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Results from ADVANCE: A phase I/II open-label non-randomised safety and efficacy study of the viral vectored ChAdOx1-MVA 5T4 (VTP-800) vaccine in combination with PD-1 checkpoint blockade in metastatic prostate cancer (On-Demand) - Jul 21, 2020 - Abstract #ESMO2020ESMO_955;
P1, P1/2
Patients received 2 cycles of ChAdOx1-MVA 5T4 (VTP-800) vaccination and three nivolumab infusions...602705 (Project IMPROVE) and Vaccitech Ltd. Clinical trial identification: NCT03815942.
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), TroVax (MVA 5T4) / Oxford Biomedica, PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
[VIRTUAL] DEVELOPMENT OF A NEXT GENERATION 24-VALENT PNEUMOCOCCAL CONJUGATE VACCINE USING SITE-SPECIFIC CARRIER PROTEIN CONJUGATION () - Jun 22, 2020 - Abstract #ISPPD2020ISPPD_143;
Clinical trial identification: NCT03815942. These results demonstrate the utility of CFPS technology in the production of the eCRM carrier protein that enables site-specific conjugation, creating the foundation for a next generation broad-valency PCV.
- | TroVax (MVA 5T4) / Oxford Biomedica
#SutroVax Announces Name Change to #Vaxcyte https://t.co/3huRU04yzX (Twitter) - May 27, 2020
- TroVax (MVA 5T4) / Oxford Biomedica, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Phase I/II open label nonrandomized safety and efficacy study of the viral vectored ChAdOx1-MVA 5T4 immunotherapy in combination with PD-1 checkpoint blockade in intermediate-risk localized or locally advanced prostate cancer and advanced metastatic prostate cancer. (Poster Board 234) - Apr 29, 2020 - Abstract #ASCO2020ASCO_1439;
P1, P1/2
Cohort 1 will receive one cycle of ChAdOx1-MVA 5T4 immunotherapy and a single nivolumab infusion...Research Funding: Grant agreement No. 602705
- || TroVax (MVA 5T4) / Oxford Biomedica, PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
SutroVax lands another $100M+ in upstart quest against Pfizer’s blockbuster Prevnar 13 https://t.co/t0XoVw2D4h (Twitter) - Mar 26, 2020
- ||| TroVax (MVA 5T4) / Oxford Biomedica
Trial completion: TRIOC: The Activity of TroVax (clinicaltrials.gov) - May 9, 2019
P2, N=94, Completed, Sponsor: University College, London
602705 Active, not recruiting --> Completed
- ||| TroVax (MVA 5T4) / Oxford Biomedica
Enrollment closed: TRIOC: The Activity of TroVax (clinicaltrials.gov) - Dec 15, 2017
P2, N=97, Active, not recruiting, Sponsor: University College, London
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| TroVax (MVA 5T4) / Oxford Biomedica
Enrollment change, Trial primary completion date: TRIOC: The Activity of TroVax (clinicaltrials.gov) - Nov 1, 2017
P2, N=97, Recruiting, Sponsor: University College, London
Recruiting --> Active, not recruiting N=75 --> 97 | Trial primary completion date: May 2017 --> May 2019
- || TroVax (MVA 5T4) / Oxford Biomedica
Trial primary completion date: TRIOC: The Activity of TroVax (clinicaltrials.gov) - Jun 10, 2016
P2, N=75, Recruiting, Sponsor: University College, London
N=75 --> 97 | Trial primary completion date: May 2017 --> May 2019 Trial primary completion date: May 2016 --> May 2017
- ||| TroVax (MVA 5T4) / Oxford Biomedica
Enrollment change: TRIOC: The Activity of TroVax (clinicaltrials.gov) - Sep 30, 2015
P2, N=75, Recruiting, Sponsor: University College, London
Trial primary completion date: May 2016 --> May 2017 N=100 --> 75
- | TroVax (MVA 5T4) / Oxford Biomedica
Trial completion, Metastases: A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=25, Completed, Sponsor: Oxford BioMedica
N=100 --> 75 Recruiting --> Completed
- TroVax (MVA 5T4) / Oxford Biomedica
Enrollment open: TRIOC: The Activity of TroVax (clinicaltrials.gov) - Dec 2, 2013
P2, N=100, Recruiting, Sponsor: University College, London
Recruiting --> Completed Not yet recruiting --> Recruiting
- TroVax (MVA 5T4) / Oxford Biomedica
Trial initiation date: SKOPOS: A Phase II Trial to Assess TroVax (clinicaltrials.gov) - Feb 26, 2013
P2, N=26, Recruiting, Sponsor: Wales Cancer Trials Unit
Not yet recruiting --> Recruiting Initiation date: Apr 2012 --> Dec 2012
- TroVax (MVA 5T4) / Oxford Biomedica
Enrollment open: SKOPOS: A Phase II Trial to Assess TroVax (clinicaltrials.gov) - Feb 26, 2013
P2, N=26, Recruiting, Sponsor: Wales Cancer Trials Unit
Initiation date: Apr 2012 --> Dec 2012 Not yet recruiting --> Recruiting
- TroVax (MVA 5T4) / Oxford Biomedica
Trial termination: TroVax (clinicaltrials.gov) - Nov 25, 2012
P2, N=25, Terminated, Sponsor: Oxford BioMedica
Not yet recruiting --> Recruiting Recruiting --> Terminated
- TroVax (MVA 5T4) / Oxford Biomedica
Enrollment change: TroVax (clinicaltrials.gov) - Nov 25, 2012
P2, N=25, Terminated, Sponsor: Oxford BioMedica
Recruiting --> Terminated N=80 --> 25
- TroVax (MVA 5T4) / Oxford Biomedica
Enrollment change, Metastases: S0348 Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Breast Cancer in Remission (clinicaltrials.gov) - Nov 14, 2012
P2, N=0, Withdrawn, Sponsor: Southwest Oncology Group
N=80 --> 25 N=120 --> 0
- TroVax (MVA 5T4) / Oxford Biomedica
New P2 trial: SKOPOS: A Phase II Trial to Assess TroVax (clinicaltrials.gov) - Apr 1, 2012
P2, N=26, Recruiting, Sponsor: Wales Cancer Trials Unit
- | TroVax (MVA 5T4) / Oxford Biomedica
New P2 trial: TRIOC: The Activity of TroVax (clinicaltrials.gov) - Mar 14, 2012
P2, N=100, Recruiting, Sponsor: University College, London